ATYs306Q6fE

70
STABILITY Investigators. The ABC (age, biomarkers, clinical history) stroke risk
score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur
Heart J. 2016;37:1582–90.
383. Gage BF, Yan Y, Milligan PE,Waterman AD, Culverhouse R, RichMW, Radford MJ.
Clinical classification schemes for predicting hemorrhage: results from the
National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151:713–9.
384. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel userfriendly
score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial
fibrillation: the Euro Heart Survey. Chest. 2010;138:1093–100.
385. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE.
A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA
(Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol.
2011;58:395–401.
386. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for
ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the
Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33:1500–10.
387. Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz
MD, Held C, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Granger CB, Wallentin L,
ARISTOTLE and RE-LY Investigators. The novel biomarker-based ABC (age,
biomarkers, clinical history)-bleeding risk score for patients with atrial
fibrillation: a derivation and validation study. Lancet. 2016;387:2302–11.
388. O’Brien EC, Simon DN, Thomas LE, Hylek EM, Gersh BJ, Ansell JE, Kowey PR,
Mahaffey KW, Chang P, Fonarow GC, Pencina MJ, Piccini JP, Peterson ED. The
ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial
fibrillation. Eur Heart J. 2015;36:3258–64.
389. Loewen P, Dahri K. Risk of bleeding with oral anticoagulants: an updated
systematic review and performance analysis of clinical prediction rules. Ann
Hematol. 2011;90:1191–200.
390. Olesen JB, Lip GY, Hansen PR, Lindhardsen J, Ahlehoff O, Andersson C,Weeke P,
Hansen ML, Gislason GH, Torp-Pedersen C. Bleeding risk in ‘real world’ patients
with atrial fibrillation: comparison of two established bleeding prediction
schemes in a nationwide cohort. J Thromb Haemost. 2011;9:1460–7.
391. Van Staa TP, Setakis E, Di Tanna GL, Lane DA, Lip GY. A comparison of risk
stratification schemes for stroke in 79,884 atrial fibrillation patients in general
practice. J Thromb Haemost. 2011;9:39–48.
392. Roldan V, Marin F, Manzano-Fernandez S, Gallego P, Vilchez JA, Valdes M, Vicente
V, Lip GY. The HAS-BLED score has better prediction accuracy for major bleeding
than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial
fibrillation. J Am Coll Cardiol. 2013;62:2199–204.
393. Wallentin L, Hijazi Z, Andersson U, Alexander JH, De Caterina R, Hanna M,
Horowitz JD, Hylek EM, Lopes RD, Asberg S, Granger CB, Siegbahn A, ARISTOTLE
Investigators. Growth differentiation factor 15, a marker of oxidative stress and
inflammation, for risk assessment in patients with atrial fibrillation: insights
from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in
Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2014;130:1847–58.
394. Raunso J, Selmer C, Olesen JB, Charlot MG, Olsen AM, Bretler DM, Nielsen JD,
Dominguez H, Gadsboll N, Kober L, Gislason GH, Torp-Pedersen C, Hansen ML.
Increased short-term risk of thrombo-embolism or death after interruption of
warfarin treatment in patients with atrial fibrillation. Eur Heart J. 2012;33:
1886–92.
395. Sjogren V, Grzymala-Lubanski B, Renlund H, Friberg L, Lip GY, Svensson PJ,
Sjalander A. Safety and efficacy of well managed warfarin. A report from the
Swedish quality register Auricula. Thromb Haemost. 2015;113:1370–7.
396. Graham DJ, Reichman ME,Wernecke M, Zhang R, Southworth MR, Levenson M,
Sheu TC, Mott K, Goulding MR, Houstoun M, MaCurdy TE,Worrall C, Kelman JA.
Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated
with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation.
2015;131:157–64.
397. Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of
anticoagulation control among patients with atrial fibrillation on warfarin: the
SAMe-TT(2)R(2) score. Chest. 2013;144:1555–63.
398. Lip GY, Haguenoer K, Saint-Etienne C, Fauchier L. Relationship of the SAMe-TT(2)
R(2) score to poor-quality anticoagulation, stroke, clinically relevant bleeding,
and mortality in patients with atrial fibrillation. Chest. 2014;146:719–26.
399. Gallego P, Roldan V, Marin F, Galvez J, Valdes M, Vicente V, Lip GY. SAMe-TT2R2
score, time in therapeutic range, and outcomes in anticoagulated patients with
atrial fibrillation. Am J Med. 2014;127:1083–8.
400. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ,
Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, Khder Y, Lobmeyer MT,
Maas H, Voigt JU, Simoons ML, Van deWerf F, RE-ALIGN Investigators. Dabigatran
versus warfarin in patients with mechanical heart valves. N Engl J Med.
2013;369:1206–14.
401. Olesen JB, Sorensen R, Hansen ML, Lamberts M,Weeke P, Mikkelsen AP, Kober L,
Gislason GH, Torp-Pedersen C, Fosbol EL. Non-vitamin K antagonist oral
anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish
nationwide descriptive data 2011–2013. Europace. 2015;17:187–93.
402. Hylek EM, Held C, Alexander JH, Lopes RD, De Caterina R, Wojdyla DM, Huber K,
Jansky P, Steg PG, Hanna M, Thomas L,Wallentin L, Granger CB. Major bleeding in
patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE
Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in
Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll
Cardiol. 2014;63:2141–7.
403. Flaker GC, Eikelboom JW, Shestakovska O, Connolly SJ, Kaatz S, Budaj A, Husted
S, Yusuf S, Lip GY, Hart RG. Bleeding during treatment with aspirin versus
apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban
versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who
have failed or are unsuitable for vitamin K antagonist treatment (AVERROES)
trial. Stroke. 2012;43:3291–7.
404. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L, Randomized
Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified
events in the RE-LY trial. N Engl J Med. 2010;363:1875–6.
405. Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, Kuder JF, Deenadayalu
N, Jarolim P, Betcher J, Shi M, Brown K, Patel I, Mercuri M, Antman EM. Association
between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an
analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Lancet. 2015;385:2288–95.
406. Beyer-Westendorf J, Forster K, Pannach S, Ebertz F, Gelbricht V, Thieme C,
Michalski F, Kohler C, Werth S, Sahin K, Tittl L, Hansel U, Weiss N. Rates,
management, and outcome of rivaroxaban bleeding in daily care: results from
the Dresden NOAC registry. Blood. 2014;124:955–62.
407. Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, van Eickels M, Turpie
AG, XANTUS Investigators. XANTUS: a real-world, prospective, observational
study of patients treated with rivaroxaban for stroke prevention in atrial
fibrillation. Eur Heart J. 2016;37:1145–53.
408. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P,
Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ, RE-LY
investigators. Efficacy and safety of dabigatran compared with warfarin at
different levels of international normalised ratio control for stroke prevention in
atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376:975–83.
409. Piccini JP, Hellkamp AS, Lokhnygina Y, Patel MR, Harrell FE, Singer DE, Becker RC,
Breithardt G, Halperin JL, Hankey GJ, Berkowitz SD, Nessel CC, Mahaffey KW, Fox
KA, Califf RM, ROCKET AF Investigators. Relationship between time in therapeutic
range and comparative treatment effect of rivaroxaban and warfarin: results
from the ROCKET AF trial. J Am Heart Assoc. 2014;3:e000521.
410. Olesen JB, Lip GY, Kamper AL, Hommel K, Kober L, Lane DA, Lindhardsen J,
Gislason GH, Torp-Pedersen C. Stroke and bleeding in atrial fibrillation with
chronic kidney disease. N Engl J Med. 2012;367:625–35.
411. Albertsen IE, Rasmussen LH, Overvad TF, Graungaard T, Larsen TB, Lip GY. Risk of
stroke or systemic embolism in atrial fibrillation patients treated with warfarin:
A systematic review and meta-analysis. Stroke. 2013;44:1329–36.
412. Hart RG, Pearce LA, Asinger RW, Herzog CA. Warfarin in atrial fibrillation
patients with moderate chronic kidney disease. Clin J Am Soc Nephrol. 2011;6:
2599–604.
413. Friberg L, Benson L, Lip GY. Balancing stroke and bleeding risks in patients with
atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study.
Eur Heart J. 2014:36:297–306.
414. Jun M, James MT, Manns BJ, Quinn RR, Ravani P, Tonelli M, Perkovic V,
Winkelmayer WC, Ma Z, Hemmelgarn BR. The association between kidney
function and major bleeding in older adults with atrial fibrillation starting
warfarin treatment: population based observational study. BMJ. 2015;
350:h246.
415. Del-Carpio Munoz F, Gharacholou SM, Munger TM, Friedman PA, Asirvatham SJ,
Packer DL, Noseworthy PA. Meta-Analysis of Renal Function on the Safety and
Efficacy of Novel Oral Anticoagulants for Atrial Fibrillation. Am J Cardiol.
2016;117:69–75.
416. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, HackeW, Oldgren J,
Sinnaeve P, Camm AJ, Kirchhof P. Updated European Heart Rhythm Association
Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients
with non-valvular atrial fibrillation. Europace. 2015;17:1467–507.
417. Zimmerman D, Sood MM, Rigatto C, Holden RM, Hiremath S, Clase CM. Systematic
review and meta-analysis of incidence, prevalence and outcomes of atrial
fibrillation in patients on dialysis. Nephrol Dial Transplant. 2012;27:3816–22.
418. Marinigh R, Lane DA, Lip GY. Severe renal impairment and stroke prevention in
atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am
Coll Cardiol. 2011;57:1339–48.
419. Wizemann V, Tong L, Satayathum S, Disney A, Akiba T, Fissell RB, Kerr PG, Young
EW, Robinson BM. Atrial fibrillation in hemodialysis patients: clinical features
and associations with anticoagulant therapy. Kidney Int. 2010;77:1098–106.
420. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with
increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc
Nephrol. 2009;20:2223–2233.
421. Winkelmayer WC, Liu J, Setoguchi S, Choudhry NK. Effectiveness and safety of
warfarin initiation in older hemodialysis patients with incident atrial fibrillation.
Clin J Am Soc Nephrol 2011;6:2662–2668.
422. Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E,
Humphries KH, Tu JV, Behlouli H, Guo H, Pilote L. Warfarin use and the risk for
stroke and bleeding in patients with atrial fibrillation undergoing dialysis.
Circulation. 2014;129:1196–203.
423. Bonde AN, Lip GY, Kamper AL, Hansen PR, Lamberts M, Hommel K, Hansen ML,
Gislason GH, Torp-Pedersen C, Olesen JB. Net clinical benefit of antithrombotic
therapy in patients with atrial fibrillation and chronic kidney disease:
a nationwide observational cohort study. J Am Coll Cardiol. 2014;64:2471–82.
424. Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW. Dabigatran and
rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation.
2015;131:972–79.
425. Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW,
Ezekowitz MD, Reilly PA, Siegbahn A, Yusuf S, Wallentin L. Efficacy and safety of
dabigatran compared with warfarin in relation to baseline renal function in
patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term
Anticoagulation Therapy) trial analysis. Circulation. 2014;129:961–70.
426. Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, Paolini JF, Hankey
GJ, Mahaffey KW, Patel MR, Singer DE, Califf RM. Prevention of stroke and